C linical trials of medical therapy to prevent progression in calcific aortic valve disease (CAVD) are hampered by the lack of sensitive measures of disease activity in the valve leaflets. Although the long-term goal of therapy is to prevent adverse cardiovascular outcomes, including mortality and aortic valve replacement, these end points have several limitations. First, the hard end point of mortality is frequently affected by comorbid conditions. Patients with CAVD typically are elderly, with a high prevalence of coronary and noncardiac disease, so that isolating the effect of valve obstruction on survival is problematic. Second, the end point of valve replacement for symptom onset reflects considerable physician variation in the threshold for intervention, as well as patient preferences. In addition, some patients are not promptly referred for valve replacement at symptom onset, sometimes inappropriately but often because of concerns about surgical risk or patient factors such as extreme age, dementia, or a severely reduced life expectancy due to coexisting conditions. Inclusion of these end points in clinical trials might obscure any benefit of medical therapy. Finally, clinical outcomes provide limited information about the mechanism of benefit; for example, medical therapy might improve outcomes by effects on coronary disease or ventricular function rather than affecting the disease process in the valve leaflets.
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Hemodynamic measures of aortic stenosis (AS) severity provide some insight into the disease process. Noninvasive Doppler velocity, gradient, and valve area measurements have provided the foundation of our knowledge about CAVD progression and are useful measures for evaluating the effects of therapy on valve obstruction in clinical trials. Yet even hemodynamic assessment is not the ideal measure of disease because stenosis occurs late in the clinical course, may not be a sensitive marker of changes in the leaflets once significant disease is present, and is not useful for studying early disease. Similarly, looking at the left ventricular response to AS reflects late and longstanding disease and not the early disease process. Even though newer imaging approaches allow detection of diastolic dysfunction and myocardial fibrosis before overt ventricular hypertrophy is evident, these changes still reflect disease severe enough to cause hemodynamic effects. We now understand that calcific AS is the end stage of a disease that progresses from microscopic early changes to aortic sclerosis and then, in a subset of patients, to severe AS. To affect this disease process, we need to be able to see the earliest stages of disease so that we can measure the effects of targeted therapy on the microscopic processes in the leaflets themselves. Progress in the understanding, diagnosis, and treatment of CAVD has been hindered by our inability to spatially resolve and quantify in vivo the dynamic molecular events associated with early calcific changes in valves.
Current Experimental and Clinical Approaches to Valve Imaging
Recent studies have shown that innovative optical molecular imaging employing near-infrared fluorescence imaging agents enables simultaneous in vivo visualization of early mineralization, allowing measurement of inflammation and osteogenic activity associated with early CAVD. 1 These studies extended a paradigm of inflammation-dependent mechanisms of calcification as opposed to the long-held belief that CAVD is an inevitable consequence of aging. Molecular imaging visualizes 3 stages of CAVD and demonstrates that inflammation precedes calcification ( Figure) . During inflammation (the initiation phase), activated macrophages produce pro-osteogenic factors that induce the transition of valvular interstitial myofibroblasts into osteoblast-like cells. Severe proinflammatory conditions further enhance inflammation and the formation of microcalcifications, contributing to more abundant calcium deposition and leaflet stiffening (the propagation phase). During these early stages, when calcification is accompanied closely by inflammation, medical therapies targeting proinflammatory and proosteogenic pathways might retard osteogenic changes. Sensitive diagnostic imaging tools are needed to accomplish this goal. Late-stage advanced calcification, in contrast, is readily detected by conventional imaging modalities but is difficult to treat. Recent clinical trials support these observations, showing that statins cannot prevent CAVD because of late implementation after calcification has progressed to the irreversible stage. The highest-resolution noninvasive clinical imaging modality currently has a resolution of Ϸ1 mm, which is insufficient to visualize cells and early calcification. Microoptical coherence tomography (OCT), a novel form of optical imaging technology with 1-m resolution, was developed recently. 2 features, such as cholesterol crystals, macrophages, and structural proteins, can be visualized by OCT. Because OCT data are 3-dimensional and acquired from intact specimens, this technology provides histological-level resolution with the speed and reliability of imaging in vivo. This method is superior to near-infrared molecular imaging because it does not require injection of molecular imaging agents and therefore may be translated to human patients more easily. The major disadvantages of near-infrared molecular imaging and OCT are limited tissue penetration and the potential need of an invasive approach. More established noninvasive diagnostic imaging modalities currently allow identification of significant AS and risk stratification of patients with suspected CAVD. Echocardiography has long been a useful clinical tool for evaluation of leaflet motion and hemodynamic obstruction, but it does not have the resolution for quantifying and monitoring aortic valve calcium at early stages, even with newer 3-dimensional approaches. Computed tomography is a useful tool for the assessment of valve anatomy, particularly during planning for transcatheter aortic valve implantation, and is an accurate technology for quantification of established, but not early, valve calcification. 3 Cardiac magnetic resonance imaging provides accurate, reproducible, and noninvasive data on left ventricle volumes and function and has the potential for quantification of valve obstruction but offers little insight into the disease process in the valve leaflets with current instrumentation. 4
Positron Emission Tomography Imaging as a Measure of Aortic Valve Inflammation and Calcification
During the last decade, it has become clear that CAVD is an actively regulated disease process rather than mere degeneration and that inflammation is critical in its initiation. 5 No clinical data, however, have directly linked inflammation and calcification during the progression of CAVD. A primary reason for the lack of such studies is that a reliable technology to noninvasively measure aortic valve inflammation and calcium burden remains unavailable in a clinical setting. Emerging evidence indicates that positron emission tomography (PET) imaging may noninvasively assess inflammation in the aortic valves of patients with AS. 6 In this issue of Circulation, Dweck et al 7 used PET imaging combined with computed tomography and 2 common PET tracers that target inflammation and calcification to investigate the feasibility of this approach. In addition, they measured the relative contributions of inflammation and calcification at different stages of CAVD by administration of both tracers to the same patients. The glucose analogue 18F-fluorodeoxyglucose (18F-FDG), an imaging agent approved for clinical use, is taken up by cells through glucose transport proteins. After phosphorylation, 18F-FDG becomes trapped within macrophages, proinflammatory phagocytes with high metabolic requirements. 18F-Sodium fluoride (18F-NaF) is directly incorporated into hydroxyapatite via an exchange mechanism with hydroxyl groups and thus is a potential marker of active tissue calcification. In a series of 121 adults aged Ͼ50 years, spanning the range of CAVD from normal valves to aortic sclerosis to severe stenosis, the authors demonstrated excellent repeatability for the quantification of 18F-FDG and 18F-NaF tracers in the valve leaflets. In the early stages of CAVD, both tracers were increased, reflecting both inflammation and active calcification, and both tracers showed a progressive stepwise increase in uptake with more severe CAVD. Calcification appeared to be a more predominant process than inflammation, particularly in the later stages of CAVD, supporting our current understanding of the pathogenesis of this disease. The study provides the first demonstration that 18F-NaF can detect early calcifica-
Inflammation-dependent mechanism of calcification. Mice were coinjected with nearinfrared fluorescence nanoparticles to visualize macrophages (green) and with a spectrally distinct imaging agent to detect calcification (red). Molecular imaging detects 3 stages of calcification in calcific aortic valve disease: initiation, propagation, and late-stage calcification. tion in patients with CAVD. Importantly, 18F-NaF uptake was observed in regions remote from advanced calcification, suggesting indirectly that 18F-NaF identifies microcalcifications, which has not been possible previously with the use of noninvasive imaging in humans. Overall, increased 18F-NaF activity was observed in 45% of patients with aortic sclerosis, in 91% of patients with mild or moderate AS, and in 100% of patients with severe AS. The next steps in this line of study will be to examine more quantitatively, in a larger study population, whether the magnitude of 18F-NaF signal associates positively with CAVD progression and to validate this tracer against histological or other sensitive imaging methods. If confirmed, perhaps 18F-NaF activity could serve as a marker of disease progression in medical intervention trials.
Although this study successfully identified early calcification, the authors also found a progressive increase of valvular 18F-FDG, an agent currently used as a tracer for inflammation. Increased 18F-FDG activity was observed in 20% of patients with aortic sclerosis, in 35% of patients with mild or moderate AS, and in 52% of patients with severe AS, supporting the hypothesis that CAVD is an inflammatory disease. 1 The authors also detected somewhat elevated uptake of 18F-FDG in patients with severe AS, in contrast to previous imaging studies, which suggested that inflammation is reduced in late-stage CAVD. 6 This controversial finding could be explained by the recent study by Folco et al 8 that evaluated the effects of inflammation and hypoxia on FDG activity and found that macrophages exhibited increased glucose uptake in response to hypoxia but not to inflammatory cytokines. Because aortic valves are largely avascular structures and valve thickness is significantly increased as a result of fibrosis and calcification, we can reasonably hypothesize that aortic valve tissue suffers from a hypoxic environment during CAVD progression. This could explain the increased FDG tracer in patients with severe AS. Previous studies also found that results from FDG PET in vivo imaging studies of atherosclerosis are often inconsistent, probably because of variations in lesion composition, presence of calcification, disease severity, and degrees of hypoxia. Furthermore, FDG uptake by metabolically active cardiac myocytes surrounding aortic valve tissue produces substantial background signal, which may interfere with the FDG readout. Because FDG uptake appears to depend on multiple factors, we should interpret the findings from this study carefully.
Imaging in Clinical Trials: Understanding Mechanisms Versus Clinical End Points
Medical therapy to prevent initiation and progression of CAVD will soon be within reach as ongoing research fills the gaps in our understanding of the specific disease pathways involved at the tissue level. In translating these advances from the basic science laboratory to the clinical research trial, we need to ensure that we do not lose sight of the mechanisms of therapeutic benefit in our eagerness to affect overall clinical outcomes. Of course, making patients live longer and feel better is our goal regardless of the mechanism of benefit, but we also need to understand how a specific intervention works in order to target our therapies more effectively. Compared with outcome trials, mechanistic studies also offer the opportunity to perform initial clinical studies with a smaller patient population over a shorter time interval and at a lower cost.
The study by Dweck et al 7 has set the stage for the use of PET valve imaging as a potential marker for evaluating drug efficacy in clinical trials. Further studies are needed to establish how early PET imaging can detect CAVD and to evaluate the utility of PET for prediction of disease progression and adverse cardiovascular outcome. Although current clinical imaging approaches, such as echocardiography, remain essential for clinical management and for following CAVD progression once valve obstruction is present, PET may be the method of choice for detection of early calcification and inflammation in clinical trials. In addition, because histopathological examination is not possible during longitudinal noninvasive imaging studies (eg, echocardiography, computed tomography, PET), validated high-resolution invasive imaging modalities (eg, molecular imaging, OCT) may be required to understand the mechanisms at various stages of CAVD. Large, prospective, event-driven studies of noninvasive imaging techniques will be required to determine the place of these modalities in future clinical practice. As we evaluate potential medical therapies for CAVD, it is not enough to know if it works; we need to know why.
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